source
- Biogen posts third consecutive quarter of revenue growth, driven by Leqembi, Spinraza and Apellis productsBiogen reported $2.8 billion in revenue for the third quarter, marking its third straight period of top‑line growth. The company credited its growth portfolio, led by the Alzheimer’s therapy Leqem…
- Five newly approved drugs achieve strong launches by offering superior efficacy, pricing and accessOver the past year several newly approved therapies have entered the market with sales and uptake that far exceed analyst expectations, driven by strong clinical data, reasonable pricing and easy p…